Scientific work

Uzm. Dr. Selver Işık

79 publications. The source of the information is stated next to each publication.

Back to profile

  1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Open-access full textSource: OpenAlex

  2. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source: OpenAlex

  3. Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response

    Expert Review of Anticancer Therapy, 2026

    DOI 10.1080/14737140.2026.2657911 PMID 41950348 Source: OpenAlex

  4. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Open-access full textSource: OpenAlex

  5. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Medicina, 2026

    DOI 10.3390/medicina62030488 PMID 41901569 Open-access full textSource: OpenAlex

  6. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Open-access full textSource: OpenAlex

  7. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group

    JCO Global Oncology, 2026

    DOI 10.1200/go-26-00317 PMID 42715501 Open-access full textSource: ORCID

  8. Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15134901 PMID 42452362 Open-access full textSource: ORCID

  9. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020798 PMID 41598735 Open-access full textSource: ORCID

  10. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020890 PMID 41598826 2 citations (Europe PMC) Open-access full textSource: ORCID

  11. Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

    Medicina, 2026

    DOI 10.3390/medicina62010098 PMID 41597384 1 citation (Europe PMC) Open-access full textSource: ORCID

  12. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-35435-3 PMID 41548007 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  13. Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach

    Brain Sciences, 2026

    DOI 10.3390/brainsci16010097 PMID 41594818 Open-access full textSource: ORCID

  14. Acquired CD74–ROS1 fusion–mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report

    Journal of Chemotherapy, 2026

    DOI 10.1080/1120009x.2026.2657116 PMID 41992733 2 citations (OpenAlex) Source: OpenAlex

  15. Capecitabine-induced pneumonitis: a rare case report and literature review

    Anti-Cancer Drugs, 2026

    DOI 10.1097/cad.0000000000001839 PMID 42668437 1 citation (OpenAlex) Source: OpenAlex

  16. Digital health engagement and health literacy among cancer patients: a cross-sectional study of ICT usage patterns

    BMC Health Services Research, 2026

    DOI 10.1186/s12913-026-15432-y 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  17. Oncological Perspective on Bone-Metastatic Colorectal Cancer: a Single-Centre Experience

    Journal of Gastrointestinal Cancer, 2026

    DOI 10.1007/s12029-026-01457-3 PMID 41944932 Source: OpenAlex

  18. Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study

    Annals of Saudi Medicine, 2026

    DOI 10.5144/0256-4947.2026.169 PMID 42251515 Open-access full textSource: OpenAlex

  19. Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15176790 PMID 42739793 Open-access full textSource: OpenAlex

  20. Prognostic Value of a Seven-Factor Risk Stratification System in T3N0 Colon Cancer: A Single-Center Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62101846 PMID 42942377 Open-access full textSource: OpenAlex

  21. Healthy Lifestyle Behaviors and Health Literacy in Oncology Patients: Evaluation of Organic Food Consumption and Physical Activity

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.269303 Source: OpenAlex

  22. Real-life Comparison of FOLFOX-6 and Modified DCF Regimens for the First-Line Treatment of HER-2 Negative Metastatic Gastric Cancer

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.269337 Source: ORCID

  23. Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study

    Frontiers in Oncology, 2026

    DOI 10.3389/fonc.2026.1820227 PMID 42109666 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  24. Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14062024 PMID 40142832 16 citations (Europe PMC) Open-access full textSource: OpenAlex

  25. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14041071 PMID 40004601 9 citations (Europe PMC) Open-access full textSource: OpenAlex

  26. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

    癌症：英文版, 2025

    DOI 10.1002/cac2.70003 PMID 39927571 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  27. The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf186 PMID 40577354 Open-access full textSource: OpenAlex

  28. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

    Immunotherapy, 2025

    DOI 10.1080/1750743x.2025.2527019 PMID 40611593 Open-access full textSource: OpenAlex

  29. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

    Journal of Chemotherapy, 2025

    DOI 10.1080/1120009x.2024.2430845 PMID 39588941 1 citation (Europe PMC) Source: ORCID

  30. The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy

    Medicina, 2025

    DOI 10.3390/medicina61081449 PMID 40870493 1 citation (Europe PMC) Open-access full textSource: ORCID

  31. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1575691 Open-access full textSource: ORCID

  32. Oncological perspective on Kaposi sarcoma: A single-centre experience

    Marmara Medical Journal, 2025

    DOI 10.5472/marumj.1627569 Open-access full textSource: ORCID

  33. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Clinical and Translational Oncology, 2025

    DOI 10.1007/s12094-024-03813-w PMID 39812937 6 citations (Europe PMC) Open-access full textSource: ORCID

  34. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14654-3 PMID 40713516 1 citation (Europe PMC) Open-access full textSource: ORCID

  35. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251331540 PMID 40297625 Open-access full textSource: ORCID

  36. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis

    Medicina, 2025

    DOI 10.3390/medicina61010144 PMID 39859125 1 citation (Europe PMC) Open-access full textSource: ORCID

  37. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-18 Open-access full textSource: OpenAlex

  38. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations

    Medicina, 2025

    DOI 10.3390/medicina61071160 PMID 40731790 7 citations (OpenAlex) Open-access full textSource: OpenAlex

  39. Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study

    Annals of Saudi Medicine, 2025

    DOI 10.5144/0256-4947.2025.249 PMID 40753462 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  40. Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience

    Nutrition and Cancer, 2025

    DOI 10.1080/01635581.2025.2496371 PMID 40327413 1 citation (OpenAlex) Source: OpenAlex

  41. Colorectal Cancer Metastasizing to the Thyroid Gland: A Rare and Interesting Case

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-11 Open-access full textSource: OpenAlex

  42. Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer.

    PubMed Central, 2025

    DOI 10.5144/0256-4947.2025.18 PMID 39929787 6 citations (OpenAlex) Open-access full textSource: OpenAlex

  43. Sex-related disparities in outcomes of survival in biliary tract cancer patients

    Journal of Cancer Research and Clinical Oncology, 2025

    DOI 10.1007/s00432-025-06096-y PMID 40016575 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  44. Denovo Metastatic Primary Gastric Ewing Sarcoma/Primitive Neuroectodermal Tumor– 13 Years Follow-up: Case Report and Review of Literature

    Journal of Medicine and Medical Studies, 2025

    DOI 10.51219/jmms/guren-ak/19 Open-access full textSource: OpenAlex

  45. Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2567845 PMID 41047636 Open-access full textSource: OpenAlex

  46. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-56046-w PMID 38461209 16 citations (Europe PMC) Open-access full textSource: OpenAlex

  47. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2305066 PMID 38263804 2 citations (Europe PMC) Source: OpenAlex

  48. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102282 PMID 39709686 2 citations (Europe PMC) Source: OpenAlex

  49. Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience

    Oncology Research and Treatment, 2024

    DOI 10.1159/000537988 PMID 38565096 2 citations (Europe PMC) Open-access full textSource: ORCID

  50. Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy

    Indian journal of cancer, 2024

    DOI 10.4103/ijc.ijc_649_21 PMID 39960709 Open-access full textSource: Europe PMC